http://www.youtube.com/watch?v=9pxuBgfbid0 blu electronic cigarette commercial - blu electronic cigarettes have no ash and no offensive odor, so I can enjoy them anywhere. In my car, at work, at my favorite restaurant or even at my friends house. Four different strengths mean I can control my nicotine intake and it cost less than regular cigarettes. blu is the smarter alternative to cigarettes and the best way to take back you're freedom. blu is available at many fine retailers including, Sheetz, Ingles, Kerr Drug, Harps, Cumberland Farms, H-E-B, Scolari's and Couche-Tard.
http://youtu.be/tHPU2gR_RiI blu cigs National TV ad - I like to smoke but my old cigarettes kept me from smoking where I wanted to. blu electronic cigarettes are different. They have no ash and no offensive odor, so I can enjoy them anywhere. In my car, at work, at my favorite restaurant or even at my friends house. blu has lot's of great USA made flavors and come in four different strengths so I can control my nicotine intake and it cost less than regular cigarettes. blu is the smarter alternative to cigarettes and the best way to take back you're freedom. blu Cigs are available at many fine retailers including, Sheetz, Ingles, Kerr Drug, Harps, Cumberland Farms, H-E-B, Scolari's and Couche-Tard.
Sickle cell disease (SCD) is an inherited, lifelong chronic disorder affecting nearly 100,000 Americans and a growing global health problem that will touch nearly 30 percent more people globally in the next three decades. Though new approaches to managing SCD have led to improvements in diagnosis and supportive care, people living with the disease still have severe complications to overcome. Many are unable to access quality care and are limited by a lack of effective treatment options.
In an effort to identify unmet medical needs for people with SCD, the American Society of Hematology (ASH), along with other groups, issued the State of Sickle Cell Disease: 2016 Report, evaluating the disease in four priority areas — access to care, training and professional education, research and clinical trials, and global health. The report shows that significant improvements are needed across all areas and that, though patients are living longer, the system of care needs to change to ensure a better quality of life. To address these challenges, ASH launched the Sickle Cell Disease Coalition along with more than 20 other organizations who are issuing a call to action that will amplify the voice of the SCD community, promote SCD awareness, and transform SCD care both in the United States and around the globe.
To view the multimedia release go to:
http://www.multivu.com/players/English/7903251-american-society-hematology-sickle-cell-coalition/
